TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Eisai's Oncology Drug Finally Gets Reviewed Derek Lowe submits: So it looks like the FDA is giving Eisai's (ESALY.PK) oncology drug Eribulin (E7389) a priority review. The company had hoped to get it reviewed three years ago, but the FDA told them to get back into the clinic and collect more data. The compound is being reviewed for advanced breast cancer, and the earlier clinical data looked pretty good. (Head and neck tumors, on the other hand, didn't show much of a response). It binds to yet another site on tubulin (a popular site for various oncology agents), but in a rather complicated fashion that differs from the other agents in this category.Complete Story » seekingalpha.com |
Health Bill's New Tax Rules Under Fire Democrats may water down or repeal new tax-reporting rules that are supposed to raise $16 billion for health-care legislation, facing a chorus of criticism about the rules. online.wsj.com |
Hospital Bribe Alleged Prosecutors charged Alexander Everest with submitting forged documents and giving thousands of dollars in bribes to a hospital employee dealing with the residency applications. online.wsj.com |
BMS, Sanofi May Get Boost From Curious Plavix Study Pharmalot submits: Last year, the FDA urged doctors not to combine proton pump inhibitors such as Prilosec and Nexium with Plavix after research suggested these heartburns med could lessen the effects of the bloodthinner and, therefore, raise the risk of a heart attack. But a study published last week in The New England Journal of Medicine found the opposite result - there was no evidence of increased heart risk among patients who took both drugs compared with those taking Plavix and a placebo. “For the rank-and-file clinician and patient, I’d say right now I wouldn’t worry about this interaction,” Deepak Bhatt, a cardiologist at Brigham and Women’s Hospital in Boston and lead author of the study, told The Wall Street Journal. There are, however, some caveats. For one thing, the study - which was known as Cogent - used a version of Prilosec with different release characteristics than what is currently on the market, suggesting the results are less likely to be duplicated in the prescribing world.Complete Story » seekingalpha.com |
Tengion to Present at Piper Jaffray 22nd Annual Health Care Conference [PR Newswire] - Tengion, Inc , a leader in regenerative medicine, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion, will present at the upcoming Piper Jaffray 22nd Annual Health Care Conference on Wednesday, December 1, 2010, at 9:30 a.m. us.rd.yahoo.com |